July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Dual inhibition of Ang-2 and VEGF-A with faricimab in diabetic macular edema: Evidence for increased durability from the BOULEVARD phase 2 trial
Author Affiliations & Notes
  • Timothy Y Y Lai
    Ophthalmology & Visual Sciences, Chinese University of Hong Kong, Kowloon, Hong Kong
  • Jayashree Sahni
    Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Karen Basu
    Genentech, Inc, California, United States
  • Stefan Scheidl
    Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Jeffrey Ryuta Willis
    Genentech, Inc, California, United States
  • Aaron Osborne
    Genentech, Inc, California, United States
  • Footnotes
    Commercial Relationships   Timothy Lai, Allergan (C), Bayer (C), Boehringer Ingelheim (C), F. Hoffmann-La Roche Ltd (C), Novartis (C); Jayashree Sahni, F. Hoffmann-La Roche Ltd (E); Karen Basu, Genentech, Inc. (E); Stefan Scheidl, F. Hoffmann-La Roche Ltd (E); Jeffrey Willis, Genentech, Inc. (E); Aaron Osborne, Genentech, Inc. (E)
  • Footnotes
    Support  Yes, Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3860. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Timothy Y Y Lai, Jayashree Sahni, Karen Basu, Stefan Scheidl, Jeffrey Ryuta Willis, Aaron Osborne; Dual inhibition of Ang-2 and VEGF-A with faricimab in diabetic macular edema: Evidence for increased durability from the BOULEVARD phase 2 trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3860.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Faricimab, the first bispecific antibody designed for intraocular use, binds and neutralizes both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). Owing to the role of the angiopoietin/Tie signaling pathway in vascular stabilization, it is hypothesized that Ang-2 inhibition may provide increased durability over anti-VEGF monotherapy in diabetic macular edema (DME).

Methods : BOULEVARD (NCT02699450) evaluated the efficacy and safety of faricimab in patients with centre-involving DME. Anti–VEGF treatment-naïve (N=168 enrolled) and previously anti–VEGF-treated patients (N=61 enrolled) received intravitreal 0.3 mg ranibizumab, 1.5 mg faricimab (treatment-naïve only), or 6.0 mg faricimab, administered every 4 weeks for 20 weeks. The primary efficacy outcome was mean change in best-corrected visual acuity (BCVA) from baseline at week 24 in treatment-naïve patients. In a 16-week off-treatment observation period, durability was assessed by time-to-retreatment using pre-specified BCVA and optical coherence tomography central subfield thickness (CST) criteria.

Results : BCVA and CST improved from baseline in all treatment arms. In treatment-naïve patients, patients receiving 6.0 mg faricimab achieved statistically significant greater BCVA gains over ranibizumab (+3.6 letters, P=0.03) at Week 24. Patients treated with faricimab experienced greater reductions in mean macular cube volume from baseline at week 24 in both treatment-naïve (1.5 mg faricimab, -2.83 mm3; 6.0 mg faricimab, -2.51 mm3) and previously treated (6.0 mg faricimab, -2.46 mm3) patients than with ranibizumab (treatment-naïve, -1.53 mm3; previously-treated, -1.43 mm3). During the observation period, faricimab showed potential for longer time to retreatment compared with ranibizumab in both patient populations. Additional analyses of durability from the off-treatment observation period will be presented.

Conclusions : BOULEVARD met its primary endpoint: faricimab demonstrated greater visual acuity gains versus ranibizumab at week 24 in treatment-naïve patients. Additional analysis of phase 2 data suggests faricimab has a potential for extended durability in both treatment-naïve and previously treated patients compared with anti-VEGF monotherapy. Durability of faricimab will be further explored in the ongoing phase 3 YOSEMITE (NCT03622580) and RHINE (NCT03622593) studies.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×